Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development
Natalia Robledinos-Antón1,2, Raquel Fernández-Ginés1,2, Gina Manda3
1Instituto de Investigaciones Biomédicas "Alberto Sols" UAM-CSIC, Instituto de Investigación Sanitaria La Paz (IdiPaz) and Department of Biochemistry, Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain.
Abstract:
The transcription factor NRF2 (nuclear factor erythroid 2-related factor 2) triggers the first line of homeostatic responses against a plethora of environmental or endogenous deviations in redox metabolism, proteostasis, inflammation, etc. Therefore, pharmacological activation of NRF2 is a promising therapeutic approach for several chronic diseases that are underlined by oxidative stress and inflammation, such as neurodegenerative, cardiovascular, and metabolic diseases. A particular case is cancer, where NRF2 confers a survival advantage to constituted tumors, and therefore, NRF2 inhibition is desired. This review describes the electrophilic and nonelectrophilic NRF2 activators with clinical projection in various chronic diseases. We also analyze the status of NRF2 inhibitors, which at this time provide proof of concept for blocking NRF2 activity in cancer therapy.
Insights
Nuclear factor erythroid 2-related factor 2 (NRF2) activation shows therapeutic potential for chronic diseases linked to oxidative stress. Conversely, NRF2 inhibition is explored for cancer therapy, targeting tumor survival.
Area of Science:
- Molecular Biology
- Biochemistry
- Pharmacology
Background:
- Nuclear factor erythroid 2-related factor 2 (NRF2) is a key transcription factor regulating cellular responses to stress.
- NRF2 activation protects against oxidative stress and inflammation, implicated in chronic diseases.
- In cancer, NRF2 promotes tumor cell survival, making its inhibition a therapeutic target.
Purpose of the Study:
- To review NRF2 activators with clinical potential for chronic diseases.
- To analyze the current status of NRF2 inhibitors for cancer therapy.
Main Methods:
- Literature review of NRF2 activators (electrophilic and nonelectrophilic).
- Analysis of NRF2 inhibitors and their role in cancer therapy.
Main Results:
- NRF2 activators are promising for treating neurodegenerative, cardiovascular, and metabolic diseases.
- NRF2 inhibitors have demonstrated proof of concept for blocking NRF2 in cancer.
Conclusions:
- Pharmacological modulation of NRF2 offers dual therapeutic strategies: activation for chronic diseases and inhibition for cancer.
- Further research into NRF2 pathways could yield novel treatments for a range of conditions.
Related Concept Videos
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Thermodynamics: Chemical Potential and Activity
The thermodynamic equilibrium constant is more accurately defined in terms of activity rather than concentration.
Potential Energy
Chemical bonds that form attractive forces between atoms also contain potential energy, called chemical energy. When a chemical reaction...
Standard Electrode Potentials


